Avexa Limited (AVX.AX) Closes ATC’s Phase III Trial to Evaluate Data
10/2/2009 8:32:58 AM
MELBOURNE--(BUSINESS WIRE)--Avexa Limited (ASX:AVX) today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
comments powered by